Annovis Bio has enrolled 850 patients with early Alzheimer's disease in a Phase 3 trial of Buntanetap, a daily oral therapeutic targeting pTau217 pathology. The dual-endpoint design will assess both symptomatic improvement at six months and disease-modifying effects at 18 months, with regulatory submissions anticipated in 2027-2028.
Key Points
- 850 patients enrolled with pTau217-confirmed AD across 83 US sites
- Dual readout design: symptomatic effects at 6 months, disease modification at 18 months
- Buntanetap targets early AD with MMSE scores 20-28; data readouts Q1 2027 and Q1 2028
Longevity Analysis
This trial represents a shift toward earlier intervention in Alzheimer's disease, focusing on patients with documented tau pathology before cognitive decline becomes severe. The dual-endpoint structure—measuring both symptom management and underlying disease arrest—reflects a more comprehensive approach to neurodegeneration, addressing both immediate quality of life and long-term cognitive resilience. Successful disease modification would establish a framework for slowing neuroinflammatory cascade progression, a critical distinction from symptomatic-only interventions, with implications for how clinicians might approach prevention and early treatment strategies in at-risk populations.
Original published by Longevity.Technology.